224776-32-3

Basic information

• Product Name: methyl 3-(1-methyl-1H-pyrazol-4-yl)propanoate
• Synonyms: methyl 3-(1-methyl-1H-pyrazol-4-yl)propanoate
• CAS NO: 224776-32-3
• Molecular Formula: C8H12N2O2
• Molecular Weight: 168.19308
• Mol File: 224776-32-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 3-(1-methyl-1H-pyrazol-4-yl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(1-methyl-1H-pyrazol-4-yl)propanoate(224776-32-3)
• EPA Substance Registry System: methyl 3-(1-methyl-1H-pyrazol-4-yl)propanoate(224776-32-3)

Safety Data

• Hazardous Substances Data: 224776-32-3(Hazardous Substances Data)

Upstream product

• 146098-28-4 methyl 3-(1-methylpyrazol-4-yl)acrylate 
• 25016-11-9 1-methylpyrazole-4-carbaldehyde 
• 67-56-1 methanol 
• 796845-56-2 3-(1-methylpyrazol-4-yl)propanoic acid 
• 1295583-21-9 methyl (2E)-3-(1-methyl-1H-pyrazol-4-yl)prop-2-enoate 
• 689251-97-6 (E)-3-(1-methyl-1H-pyrazol-4-yl)acrylic acid 

Downstream Products

• 1380427-95-1 2-((3-methoxy-4-(3-(trifluoromethyl)phenoxy)benzyl)thio)-5-((1-methyl-1H-pyrazol-4-yl)methyl)pyrimidin-4(1H)-one 
• 1380427-97-3 C₂HF₃O₂*C₂₅H₂₃F₃N₄O₃S 
• 1380428-00-1 5-[2-({5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1,4-dihydro-2-pyrimidinyl}thio)ethyl]-2-{[3-(trifluoromethyl)phenyl]oxy}benzonitrile 
• 1380428-06-7 2-((4-(4-chloro-3-(trifluoromethyl)phenoxy)phenethyl)thio)-5-((1-methyl-1H-pyrazol-4-yl)methyl)pyrimidin-4(1H)-one 
• 1380428-07-8 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]thio}-1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-20-5 5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-{[2-(4-{[4-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]oxy}-4(1H)-pyrimidinone 
• 1380426-85-6 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-36-3 5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-{[2-(4-{[6-(trifluoromethyl)-3-pyridinyl]oxy}phenyl)ethyl]oxy}-4(1H)-pyrimidinone 
• 1380428-49-8 2-[(2-{4-[(3-chloro-4-methylphenyl)oxy]phenyl}ethyl)oxy]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-52-3 2-[(2-{4-[(4-chloro-3-methylphenyl)oxy]phenyl}ethyl)oxy]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-56-7 2-[(2-{4-[(3-fluoro-4-methylphenyl)oxy]phenyl}ethyl)oxy]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380426-88-9 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-59-0 5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-[(2-{4-[(6-methyl-2-pyridinyl)oxy]phenyl}ethyl)oxy]-4(1H)-pyrimidinone 
• 1380428-63-6 2-{[2-(4-{[3-chloro-5-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]oxy}-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 

Relevant articles and documents

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the filed of pharmarcutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) amd a preparation method thereof, a pharmarcutical composition with the compounds as active components, and a use of the azole compounds and the pharmarcutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as deinfed in the specifictaion.

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the field of pharmaceutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) and a preparation method thereof, a pharmaceutical composition with the compounds as active components, and a use of the azole compounds and the pharmaceutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as defined in the specification.

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).

Pyrimidinone compounds

Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.